The relevance of BRCA genetics to prostate cancer pathogenesis and treatment.
Clin Adv Hematol Oncol., Oct;9(10):748-55 (2011)
Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Clin Genitourin Cancer., Sep;9(1):39-45 (2011)
Novel antibody approaches for T-cell lymphomas.
Clin Lymphoma Myeloma., Dec;8 Suppl 5:S193-8 (2008)
Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
Cancer Epidemiol. Biomarkers Prev., Jun;18(6):1904-13 (2009)
Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Clin Genitourin Cancer., Sep;9(1):31-8 (2011)
Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Prostate Cancer Prostatic Dis., 11(1):79-87 (2008)
Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Cancer Gene Ther., Jun;14(6):583-9 (2007)
Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Oncogene., Sep;25(44):5942-52 (2006)
Mapping of the molecular determinants involved in the interaction between eps15 and AP-2.
Cancer Res., Jan;57(2):240-5 (1997)